Drug profile · INN
caffeine
PEYONA (PREVIOUSLY NYMUSA)
caffeine (PEYONA (PREVIOUSLY NYMUSA)) is a adenosine receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.
Drug details — caffeine
- US status
- approved
- Class
- Nervous system (N06)
- Route
- RECTAL
- Patents
- 0
- Programs
- 11
- Data quality
- 0.84
Quick answer
caffeine (PEYONA (PREVIOUSLY NYMUSA)) is a adenosine receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.
Key facts
Mechanism of action
Adenosine receptor antagonist
Primary target: Adenosine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is caffeine?
caffeine (PEYONA (PREVIOUSLY NYMUSA)) is a adenosine receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.
What is the brand name for caffeine?
PEYONA (PREVIOUSLY NYMUSA) is a marketed brand name for caffeine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of caffeine?
caffeine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.